| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.77 |
| 52 Week High | CN¥33.46 |
| 52 Week Low | CN¥20.38 |
| Beta | 0.67 |
| 1 Month Change | -8.19% |
| 3 Month Change | -0.87% |
| 1 Year Change | -30.83% |
| 3 Year Change | -50.78% |
| 5 Year Change | -20.33% |
| Change since IPO | 797.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600196 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.7% | -0.7% | -0.2% |
| 1Y | -30.8% | -15.9% | -17.8% |
Return vs Industry: 600196 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 600196 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 600196 volatility | |
|---|---|
| 600196 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 600196 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600196's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 40,370 | Deyong Wen | www.fosunpharma.com |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary
| 600196 fundamental statistics | |
|---|---|
| Market cap | CN¥54.18b |
| Earnings (TTM) | CN¥2.39b |
| Revenue (TTM) | CN¥41.40b |
25.5x
P/E Ratio1.5x
P/S RatioIs 600196 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600196 income statement (TTM) | |
|---|---|
| Revenue | CN¥41.40b |
| Cost of Revenue | CN¥21.72b |
| Gross Profit | CN¥19.68b |
| Other Expenses | CN¥17.30b |
| Earnings | CN¥2.39b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 47.54% |
| Net Profit Margin | 5.76% |
| Debt/Equity Ratio | 57.7% |
How did 600196 perform over the long term?
See historical performance and comparison